FDG-PET in the clinical management of Hodgkin lymphoma

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

FDG-PET in the clinical management of Hodgkin lymphoma. / Hutchings, Martin; Eigtved, Annika I; Specht, Lena.

I: Critical Reviews in Oncology/Hematology, Bind 52, Nr. 1, 2004, s. 19-32.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Hutchings, M, Eigtved, AI & Specht, L 2004, 'FDG-PET in the clinical management of Hodgkin lymphoma', Critical Reviews in Oncology/Hematology, bind 52, nr. 1, s. 19-32. https://doi.org/10.1016/j.critrevonc.2004.05.007

APA

Hutchings, M., Eigtved, A. I., & Specht, L. (2004). FDG-PET in the clinical management of Hodgkin lymphoma. Critical Reviews in Oncology/Hematology, 52(1), 19-32. https://doi.org/10.1016/j.critrevonc.2004.05.007

Vancouver

Hutchings M, Eigtved AI, Specht L. FDG-PET in the clinical management of Hodgkin lymphoma. Critical Reviews in Oncology/Hematology. 2004;52(1):19-32. https://doi.org/10.1016/j.critrevonc.2004.05.007

Author

Hutchings, Martin ; Eigtved, Annika I ; Specht, Lena. / FDG-PET in the clinical management of Hodgkin lymphoma. I: Critical Reviews in Oncology/Hematology. 2004 ; Bind 52, Nr. 1. s. 19-32.

Bibtex

@article{3d0660f04c7f11df928f000ea68e967b,
title = "FDG-PET in the clinical management of Hodgkin lymphoma",
abstract = "Positron emission tomography (PET) is a molecular functional imaging technique that provides qualitative and quantitative information about the localization and activity of pathophysiological processes. The most commonly used tracer for oncological purposes is 2-[18F]fluoro-2-deoxy-d-glucose (FDG). FDG-PET has within recent years become the most important nuclear medicine imaging modality in the management of lymphoma. This review summarizes the data published so far concerning the value of FDG-PET in staging, treatment monitoring, therapy planning, and follow-up of Hodgkin lymphoma (HL). FDG-PET detects more disease sites and involved organs than conventional staging procedures including computerized tomography (CT) and has a large influence on staging. FDG-PET during and after therapy appears to provide considerable prognostic information. However, the impact on patient outcome is not clear since no controlled trials are conducted and follow-up periods are generally short. The value of dual-modality PET/CT and its potential role in the radiotherapy planning is discussed.",
author = "Martin Hutchings and Eigtved, {Annika I} and Lena Specht",
note = "Keywords: Drug Monitoring; Fluorodeoxyglucose F18; Hodgkin Disease; Humans; Neoplasm Staging; Positron-Emission Tomography; Radiotherapy, Adjuvant",
year = "2004",
doi = "10.1016/j.critrevonc.2004.05.007",
language = "English",
volume = "52",
pages = "19--32",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

RIS

TY - JOUR

T1 - FDG-PET in the clinical management of Hodgkin lymphoma

AU - Hutchings, Martin

AU - Eigtved, Annika I

AU - Specht, Lena

N1 - Keywords: Drug Monitoring; Fluorodeoxyglucose F18; Hodgkin Disease; Humans; Neoplasm Staging; Positron-Emission Tomography; Radiotherapy, Adjuvant

PY - 2004

Y1 - 2004

N2 - Positron emission tomography (PET) is a molecular functional imaging technique that provides qualitative and quantitative information about the localization and activity of pathophysiological processes. The most commonly used tracer for oncological purposes is 2-[18F]fluoro-2-deoxy-d-glucose (FDG). FDG-PET has within recent years become the most important nuclear medicine imaging modality in the management of lymphoma. This review summarizes the data published so far concerning the value of FDG-PET in staging, treatment monitoring, therapy planning, and follow-up of Hodgkin lymphoma (HL). FDG-PET detects more disease sites and involved organs than conventional staging procedures including computerized tomography (CT) and has a large influence on staging. FDG-PET during and after therapy appears to provide considerable prognostic information. However, the impact on patient outcome is not clear since no controlled trials are conducted and follow-up periods are generally short. The value of dual-modality PET/CT and its potential role in the radiotherapy planning is discussed.

AB - Positron emission tomography (PET) is a molecular functional imaging technique that provides qualitative and quantitative information about the localization and activity of pathophysiological processes. The most commonly used tracer for oncological purposes is 2-[18F]fluoro-2-deoxy-d-glucose (FDG). FDG-PET has within recent years become the most important nuclear medicine imaging modality in the management of lymphoma. This review summarizes the data published so far concerning the value of FDG-PET in staging, treatment monitoring, therapy planning, and follow-up of Hodgkin lymphoma (HL). FDG-PET detects more disease sites and involved organs than conventional staging procedures including computerized tomography (CT) and has a large influence on staging. FDG-PET during and after therapy appears to provide considerable prognostic information. However, the impact on patient outcome is not clear since no controlled trials are conducted and follow-up periods are generally short. The value of dual-modality PET/CT and its potential role in the radiotherapy planning is discussed.

U2 - 10.1016/j.critrevonc.2004.05.007

DO - 10.1016/j.critrevonc.2004.05.007

M3 - Journal article

C2 - 15363464

VL - 52

SP - 19

EP - 32

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 1

ER -

ID: 19371049